Publications by authors named "Ken Igawa"

Dupilumab is an interlekin-4 receptor antibody that exerts its efficacy by inhibiting the signaling pathway of interleukin-4/interleukin-13, and it is currently used clinically as a highly potent therapeutic for atopic dermatitis. However, there have been few reports on the therapeutic effect of dupilumab using long-term real-world data. To accumulate further real-world data through long-term use of dupilumab, we performed a retrospective study on the courses of patients with atopic dermatitis who were treated with dupilumab for at least 104 weeks in our university hospital.

View Article and Find Full Text PDF

Background: Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder characterized by mutations in the TSC1 and TSC2 genes, leading to the dysregulation of the mammalian target of rapamycin (mTOR) pathway. This dysregulation results in the development of benign tumors across multiple organ systems and poses significant neurodevelopmental challenges. The clinical manifestations of TSC vary widely and include subependymal giant cell astrocytomas (SEGAs), renal angiomyolipomas (AMLs), facial angiofibromas (FAs), and neuropsychiatric conditions such as autism spectrum disorder (ASD).

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to assess the effectiveness and safety of lebrikizumab when combined with topical corticosteroids in Japanese patients aged 12 and older with moderate-to-severe atopic dermatitis (AD).
  • Conducted over 16 weeks, the Phase 3 trial involved 286 participants who were randomly assigned to receive either lebrikizumab (administered every 2 or 4 weeks) or a placebo, with results showing significantly higher rates of improvement in skin condition among those receiving lebrikizumab.
  • The treatment was found to have a good safety profile, with serious adverse events being rare, though some mild to moderate side effects were more common in the lebrikizumab groups compared to the placebo
View Article and Find Full Text PDF

Introduction: In adults with moderate-to-severe atopic dermatitis (AD), rocatinlimab demonstrated significant and progressive improvement in clinical measures of disease severity compared with placebo. This post hoc analysis of a phase 2b study was undertaken to understand the disease burden and to assess the impact of rocatinlimab on patient-reported outcomes (PROs).

Methods: This analysis used baseline data from a multicenter, randomized, double-blind study of adults with moderate-to-severe AD, who completed a Worst Pruritus numerical rating scale (NRS), Sleep Disturbance NRS, and the Dermatology Life Quality Index (DLQI).

View Article and Find Full Text PDF
Article Synopsis
  • Moderate-to-severe atopic dermatitis significantly affects patients' quality of life, and the monoclonal antibody lebrikizumab, which targets IL-13, is being evaluated for its long-term effectiveness and safety in treating this condition.
  • In the ADhere-J study, patients who responded positively at week 16 received lebrikizumab combined with topical corticosteroids (TCS) during a maintenance phase, while those who did not respond received lebrikizumab with TCS as an escape option.
  • By week 68, 66-81% of initial responders maintained improvement in their condition, as shown by significant scores in both the Investigator's Global Assessment and the Eczema Area and Severity Index, highlighting
View Article and Find Full Text PDF
Article Synopsis
  • Lebrikizumab was effective in past Phase 3 trials, both alone and with topical corticosteroids, highlighting its potential for treating moderate-to-severe atopic dermatitis.
  • This study focused on Japanese patients and assessed the effects of lebrikizumab combined with low- to mid-potency topical corticosteroids over 16 weeks.
  • Results showed that lebrikizumab significantly improved various patient-reported outcomes compared to a placebo, indicating its efficacy in managing atopic dermatitis symptoms.
View Article and Find Full Text PDF

Background: Itch is the most troublesome symptom of atopic dermatitis, and it is important to assess it appropriately for optimal treatment. We discussed issues regarding itch and the most appropriate methods of assessment at the Atopic Itch Consensus Meeting (AICOM), attended by physicians and researchers with expertise in itch treatment and research.

Methods: The AICOM participants prepared a draft consensus statement that addressed the most appropriate itch assessment methods for age groups <2 years, 2-6 years, 7-14 years, and ≥15 years.

View Article and Find Full Text PDF
Article Synopsis
  • Atopic dermatitis (AD) is an inflammatory skin condition influenced by genetics, skin environment, and immune system dysfunction, particularly in T cells.
  • Rocatinlimab is a new treatment that targets the OX40 receptor on activated T cells, which play a key role in inflammatory diseases like AD.
  • In a phase 2b study, patients with moderate-to-severe AD showed significant symptom improvement when treated with rocatinlimab compared to placebo, with common side effects being fever, nasopharyngitis, and chills, indicating it may be a safe and effective option.
View Article and Find Full Text PDF

Vascular-type Ehlers-Danlos syndrome (vEDS) is caused by collagen III deficit resulting from heterogeneous mutations in , which occasionally causes sudden death due to arterial/visceral rupture. However, it is difficult to conduct basic research on the pathophysiology of vEDS. Moreover, the number of patients with vEDS is small, limiting the number of available samples.

View Article and Find Full Text PDF

The primary symptom of urticarial vasculitis (UV), which is a histopathological leukocytoclastic vasculitis disease, is an eruption that resembles urticaria. Other organs may also experience accompanying symptoms. Lung lesions with UV are mostly obstructive pulmonary disease with smoking.

View Article and Find Full Text PDF

Background: OX40 is crucial for T-cell differentiation and memory induction. The anti-OX40 antibody, rocatinlimab inhibits the OX40 pathway. We evaluated the efficacy and safety of rocatinlimab in adults with moderate-to-severe atopic dermatitis.

View Article and Find Full Text PDF

Vascular-type Ehlers-Danlos syndrome (vEDS) is an autosomal dominant inherited disorder caused by a deficit in collagen III as a result of heterogeneous mutations in the α1 type III collagen gene (). Patients with vEDS often experience the first major complications in their early 20s and >80% have at least one complication by their 40s, reducing their average life expectancy to 48 years. Most commonly, vEDS variants are heterozygous missense substitutions of a base-pair encoding a glycine (Gly) residue of the [Gly-X-Y] repeat of the protein.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to investigate the effectiveness of nemolizumab, an anti-IL-31 receptor antibody, in treating uremic pruritus in Japanese hemodialysis patients, comparing it to a placebo and an oral medication, nalfurafine.
  • Patients were divided into multiple groups receiving different doses of nemolizumab or placebo, with the primary goal being to measure changes in itching severity after 4 weeks.
  • The results showed that while some patients noticed improvements in itching, the primary endpoint of significant efficacy was not achieved, although nemolizumab was generally well-tolerated without major safety issues.
View Article and Find Full Text PDF

Vascular-type Ehlers-Danlos syndrome (vEDS) is an autosomal-dominant inherited disorder caused by a deficit in collagen III. It results from heterogeneous mutations in the α1 collagen III gene (COL3A1) and is associated with life-threatening complications, even in younger patients. However, the details of the pathogenesis underlying the COL3A1 mutation causing vEDS remain unclear.

View Article and Find Full Text PDF

A PHP Error was encountered

Severity: Warning

Message: fopen(/var/lib/php/sessions/ci_session4t2gcsmj9e3o4vdgb1q4kktraot5789c): Failed to open stream: No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 177

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: session_start(): Failed to read session data: user (path: /var/lib/php/sessions)

Filename: Session/Session.php

Line Number: 137

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once